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–Performance-enhancing drugs, 
supplements and the athlete’s heart
(The List) is reviewed annually and comments and contributions 
from the sport community regarding any proposed changes are 
welcomed and encouraged. At the same time it is recognised that 
the legitimate health needs of many athletes may frequently require 
the use of otherwise prohibited medications. The WADA Code 
provides for the administration of such medications following 
special application and a review of a particular case by a suitably 
qualified panel of clinicians.
The use of many prohibited drugs is not restricted to the elite; 
such drug-taking behaviour can be seen at virtually every level of 
sport.(5-7) It is equally important to recognise that the use of 
prohibited substances is not limited to those involved in competi-
tive activities; many young adults use a variety of drugs and other 
substances in attempts to enhance their physique or in the pursuit 
of mood-altering experiences. The use of so-called nutritional 
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INTRODUCTION
The use of performance-enhancing drugs is an unfortunate reality 
of sport.(1,2) Since 2004, responsibility for the development, 
application and oversight of international anti-doping activities has 
been vested in the World Anti-Doping Agency (WADA) head-
quartered in Montreal, Canada and supported by the international 
sport community principally through the International Olympic 
Committee (IOC), international sport organisations (ISOs), and 
international governments. Responsibility for the implementation 
of testing and adjudication procedures in sport rests with Inter-
national Sport Organisations (ISOs), National Sport Federations 
(NSFs) and National Anti-Doping Organisations (NADOs).(3) The 
development of WADA, and more specifically the adoption of the 
WADA Code, has meant that there is now consistency between 
and among sport organisations at virtually every level in the 
approach taken to address the doping issue e.g. harmonised testing 
standards, review processes and sanctions.(4)  In North America, 
professional sport organisations have been slow to adopt the 
approaches that are found more consistently throughout the rest 
of the world.
It is a committee of WADA, the “List Committee”, that ultimately 
determines what substances and methods are prohibited in sport. 
A substance can be considered for inclusion if it meets two of 
three criteria: it enhances performance; it is harmful to health; 
and/or its use contravenes the “spirit of sport”. The prohibited list 
The use of performance-enhancing drugs is an unfortunate 
reality of contemporary sport. It would be a mistake to 
believe that this is a phenomenon found only in elite sport. 
Athletes at all levels and young adults may be tempted to 
accentuate performance or physique with prohibited drugs 
or products marketed as supplements. No defi ned popu-
lations of users ingesting known quantities of known 
substances are generally available for study. Many of these 
products have been associated with adverse health effects; 
cardiac structure and function are known to be affected by 
many of the products commonly abused. Changes to the 
lipoprotein profi le, propensity for coagulation, coronary 
circulation, and ventricular function may accompany the 
use of many performance-enhancing compounds and 
methods. Anabolic steroids, other peptide hormones, sti-
mulants, erythropoietin and blood doping, have all been 
associated with signifi cant cardiovascular consequences. 
So-called nutritional supplements aggressively marketed to 
the athletically inclined, are available over the Internet 
and typically totally unregulated in the country of their 
origin. Clinicians should be aware of the problems that 
such drug use can engender, and be sensitive to the possi-
bilities of such abuse in caring for athletes and young 
patients, particularly in those presenting with unusual or 
unanticipated cardiovascular signs and symptoms.
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supplements has spawned an array of other problems for sport 
authorities and clinicians. Typically the product of a US-based, 
multi-billion-dollar industry, supplements have until recently escaped 
any meaningful forms of regulation.(8) Thus, their quality, ingredients, 
manufacture, labelling and marketing were subject to minimal 
oversight – with significant consequences for health and safety.(9)
It is difficult to quantify the degree to which doping practices are 
common. It is typical that approximately 1% of all doping-control 
tests are found to contain evidence of a prohibited substance or 
suggest the use of a prohibited method. 
Three important caveats must be understood: the true incidence 
of the use of prohibited drugs in sport is difficult to define because 
it is illicit, concealed behaviour; it is particularly difficult to develop 
clear evidence of the adverse effects of drugs or compounds 
whose use is surreptitious – the ability to develop significant clinical 
experience in defined populations is lacking; and finally, it is naive in 
the extreme to believe that a recitation of the side effects of drugs 
or doping practices, real or potential, will have significant impact in 
deterring the use of these drugs by individuals who are part of sub-
cultures where such drug-taking behaviour is the norm or en-
couraged. It is important that we understand the consequences of 
such drug-taking behaviour; it is equally important that we develop 
sensitive, realistic and thoughtful approaches to deter it.(10)
DOPING AND THE HEART
Many of the substances and methods prohibited in sport have the 
potential to cause significant health consequences. Cardiovascular 
clinicians should be aware of the nature of the adverse cardiac 
consequences that can befall those who are exposed to the hazards 
implicit in the use of certain drugs or other products that have 
been commonly used by athletes in attempts to accentuate athletic 
performance. Physicians must be aware that it is commonly the 
case that many products sold to athletes (frequently on the black 
market – often via the Internet) differ markedly in composition and 
quality further impeding our understanding of the complications 
associated with these substances. The picture becomes muddier 
when it is realised that many athletes use combinations of pro-
ducts thereby increasing the likelihood of unanticipated inter-
actions and effects. Many authors have described the array of 
complications and pathologies that can follow the use of certain 
drugs or so-called “supplements”.(8,11) 
ANABOLIC-ANDROGENIC STEROIDS
Anabolic-androgenic steroids (AAS), synthetic derivatives of testos-
terone, were initially products of the German chemical industry and 
introduced in the late 1930s to address conditions that resulted 
from a deficiency of this male hormone.(12) Ultimately researchers 
identified that these compounds accentuated anabolic processes 
and enhanced muscle size, strength and power.(12) It is speculated 
that they found application in military settings because of their 
ability to augment physical performance and aggressiveness.(13) The 
use of such hormones increased as perceptions grew that they 
were capable of enhancing libido and accentuating sport per-
formance.(14) In the post-war years their use spread to the Euro-
pean weight-lifting community and eventually to North America 
and sport communities in which strength, power and size were 
important. Soon US, Russian and East German athletes were using 
these substances either independently or under the supervision of 
sport authorities – but always surreptitiously.(15,16) The IOC pro-
hibited their use in 1974; the first testing for these drugs during 
Olympic competition took place in Montreal in 1976. In 1988 the 
Canadian sprinter, Ben Johnson, tested positive for the presence 
of the AAS stanozolol after winning the 100m final at the 1988 
Seoul Olympic Games. In recent years these drugs have been used 
extensively by those in power sports but also by athletes in a 
variety of sporting disciplines and those who seek only to enhance 
their strength and appearance. Their pharmacology is well under-
stood; their effects are protean; they are among the most com-
monly abused drugs in sport; and “designer” modifications are 
often synthesised in black market laboratories.(17) They may be 
commonly purchased in weight training facilities and other black 
market settings. They are often used in combination according to 
regimens in which “stacking” (the use of two or more steroids) and 
“cycling” (in which doses are adjusted in the course of a multi-
week cycle) are commonplace. It has been estimated that more 
than 1 million Americans use AAS; young athletes, collegiate com-
petitors, body builders, police officers and firefighters have been 
noted to be among those who ingest or inject these products.(18) 
In 1996 a national survey revealed high levels of steroid use and 
needle-sharing behaviours among 11- to 18-year-old Canadians.(19) 
Clinicians must be aware, therefore, of the ubiquitous presence of 
these drugs in many communities…and of the likelihood of seeing 
the undesirable consequences of their use.
CARDIOVASCULAR CONSEQUENCES OF AAS USE
Our ability to understand the cardiovascular consequences of 
AAS use is limited by the fact that there are no defined popula-
tions of users who have been carefully followed and evaluated. 
Our perception that the use of these drugs is harmful is fuelled 
by the numerous case reports of cardiovascular problems occurring 
in association with AAS usage. There are now numerous reports 
of atrial fibrillation, QT dispersion, myocardial infarction, cardio-
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myopathy, heart failure and other cardiovascular issues in the 
literature.(13,20-25) It has been noted that the incidence of such 
events is likely under reported.(26)
The cardiovascular effects of anabolic steroids may be mediated 
by their effect on lipids; their ability to damage myocardial tissue; 
their ability to accentuate thrombosis; and their negative effects 
on endothelial function.(27) AAS use may also contribute to the 
development of hypertension; a finding, however, that is in-
consistent.(28,29)
AAS use is known to cause a distortion of normal lipoprotein 
levels – increasing triglycerides, elevating LDL (by 11% to 100%), 
and lowering HDL (by 39% to 70%).(30,31) Notwithstanding the 
creation of an atherogenic lipid profile, it must be acknowledged 
that there is no direct evidence that AAS will cause atheroscle-
rosis.(32) It has been speculated that AAS create an atherogenic 
profile by increasing hepatic triglyceride lipase activity (HTGL) 
which catabolises HDL.(32) Lipid levels are known to return to 
normal within months of cessation of AAS use. The risk of cardiac 
disease has been estimated to be three-fold in users of AAS.(13,27)
Damage to myocardial cells is initiated by disruption of myocardial 
mitochondria and the stimulation of intrafibrillar collagen dysplasia 
resulting in the development of scar tissue. The development of 
hypertension can contribute to ventricular hypertrophy and changes 
to ventricular function.(33) Animal studies have demonstrated that 
AAS influences cardiac structure and function.(25,34) The association 
between AAS and ventricular dysfunction has been frequently 
noted.(8) More recently, echocardiographic investigations have 
revealed the relationship between long-term AAS use and both 
systolic and diastolic ventricular dysfunction.(34-37) The effects of 
AAS use may still be evident several years after their discontinu-
ation.(38) AAS use has also been noted to adversely affect right 
ventricular diastolic function.(39) It has been speculated that AAS 
could contribute directly to myocardial cell damage with resulting 
cell death and fibrosis establishing lesions that might serve to 
stimulate ventricular arrhythmias and sudden death.(27)
Multiple cases of thromboembolic disease have been reported 
among AAS users.(40) Yet, to date there is no direct evidence that 
AAS are thrombogenic in humans; studies of haemostasis in 
steroid users are rare. Nevertheless, it has been concluded that 
the use of AAS confers an enhanced pro-thrombotic state.(40)
Arterial structure and function are adversely affected by the use of 
AAS.(41) Disruption of normal nitric oxide activity is speculated to 
impair endothelial function.(13,27) Vascular distensibility has been 
shown to be lower in AAS users, providing further evidence of 
altered vascular function.(42)
Sudden cardiac death has been frequently reported among AAS 
users.(22,43-45) Yet there is no clear epidemiological data on which to 
conclude that there is a cause-effect relationship; the picture is 
complicated by poor follow-up of those who have presented with 
arrhythmias; the concomitant use of a variety of other drugs; and an 
inability to control for those who may have an inherited suscepti-
bility to arrhythmogenic disease. There is evidence that AAS use 
in association with resistance training can lead to an increased risk 
of malignant arrhythmia.(46) Some have speculated that the use of 
AAS increases the risk of life-threatening arrhythmia; the under-
lying mechanisms remain to be elucidated.(40) Superimposed upon a 
distorted and potentially atherogenic lipoprotein profile (a recog-
nised by-product of AAS use), the dramatic, intermittent elevations 
in blood pressure reported in weightlifters and body builders may 
also play a role in the development of the cerebrovascular acci-
dents reported among such athletes.(47-49) 
For many years it has been recognised that the abuse of growth 
hormone (hGH) poses significant challenge to sport authorities and 
the health of athletes.(50-52) Acromegaly, with its known relationship 
to premature cardiovascular disease, is a well-recognised complica-
tion of an abundance of this hormone; considerations are now 
being given to its impact on other aspects of cardiovascular health. 
Hypertension, dyslipidaemia and cardiomyopathy have been identi-
fied as potential areas of concern.(53) Detection of hGh poses a 
challenge to anti-doping authorities.(54)
In summary, there is concern grounded in clinical experience that 
the use of AAS contributes to an enhanced risk of cardiac disease 
and associated complications. Cardiologists should be sensitive to 
the possibility of AAS use when seeing young, athletic or muscular 
patients with pronounced dyslipidaemia, ventricular dysfunction, 
premature coronary artery disease and other cardiac presentations 
in the absence of common contributing factors. Careful questioning 
and a non-judgmental manner may reveal a history of AAS use in 
some of these patients.
STIMULANTS
The use of stimulants in sport is more than a hundred years old; 
the earliest deaths associated with doping involved stimulant abuse 
in six day bicycle races. In the 1960s the death of cyclists using 
amphetamines in the Tour de France spawned the developments, 
in 1968, of the IOC Medical Committee. These powerful stimu-
lants have been used by unscrupulous athletes and their handlers 
PERFORMANCE-ENHANCING DRUGS AND THE HEART
167
W
in
te
r 2
01
1
Vo
lu
m
e 
8 
• 
N
um
be
r 3
for many years; their ability to enhance certain sport performances 
has been understood for decades.(55,56) Testing for amphetamines 
first occurred at the 1968 Mexico City Olympic Games. Stimulant 
use continues in sport. 
Stimulants are commonly used in nearly all societies and are found 
in a variety of foodstuffs and beverages e.g. caffeine. Others are 
available as over-the-counter medications and used to treat a 
variety of common minor respiratory illnesses e.g. pseudoephedrine, 
phenylpropanolamine. All have been used by athletes in an attempt 
to accentuate performance and enhance arousal while reducing the 
perception of fatigue; their use may also be intended to enhance 
the intensity of training. It is difficult to prohibit substances which 
are used commonly in daily life or treat common illness. The use of 
stimulants continues to challenge sport authorities and poses 
specific hazards to athletes and would-be athletes alike.(57)
Caffeine, once prohibited is now permitted in sport – in part 
because it is ergogenic at doses compatible with the incidental use 
of caffeinated beverages and the ingestion of chocolate, while 
degrading performance at higher doses (a fact that is lost on many 
athletes). The use of caffeine combined with ephedrine was 
common in weight-loss products and has been shown to have 
significant effect on blood pressure.(58,59) The combination of 
these products has also been shown to enhance performance in a 
variety of exercise settings.(60,61) Ephedrine is a prohibited substance 
in sport. 
Pseudoephedrine was removed from the prohibited list (because 
of its presence the globe over in cough and cold medications) but 
has since been re-introduced with much higher detection thresh-
olds as a consequence of evidence of its use at very high doses in 
certain sports in certain nations. Notably, however, this drug is now 
being removed from many markets because of its use as a cheap 
precursor for use in the manufacture of other illicit drugs. 
Most cardiologists in urban areas will, sadly, be familiar with the 
vasospastic effects of cocaine on the coronary vasculature.(62) The 
use of this stimulant has receded from sport following a number 
of untimely and unseemly deaths associated with its use by high 
profile athletes.(62-64) Cocaine is still a prohibited drug in sport; it is 
most commonly detected as a consequence of its use as a “social 
drug of abuse” in non-sporting situations.
In South Africa there is understandable concern regarding an 
epidemic of methamphetamine use in the community.(65) While 
not typically considered as a performance-enhancer, methamphe-
tamine or “tik”, as it is commonly known in South Africa, has 
been recognised as a cause of damaged cardiac structure and 
function.(66-68) Its use may coincide with the administration of other 
performance enhancing substances in settings where social drug 
use is common; adolescent use of this drug in South Africa and 
elsewhere is burgeoning and disconcerting. 
SUPPLEMENTS
Athletes are highly disposed to purchase and consume nutritional 
supplements; a large majority of Canadian athletes at the 1996 and 
2000 Olympic Games were using a supplement of some kind (69% 
and 74% respectively).(69) Since 1994 the US Supplement industry 
has, until recently, been largely unregulated. The result has been 
that athletes (and would-be athletes) have been exposed to a 
variety of “supplements” whose nature, manufacture and marketing 
are unregulated.(70) As a consequence there have been frequent 
examples of athletes purchasing or being provided with nutritional 
products containing prohibited substances or other hazardous 
ingredients.(9,71-73) 
The popularity of nutritional supplements within the athlete 
community meant that for many years these largely unregulated 
products frequently contained quantities of ephedra alkaloids, sym-
pathomimetics that were touted to enhance performance, minimise 
the development of fatigue, and facilitate weight loss.(74) Use of 
ephedra resulted in a significant number of deaths in the sport and 
exercising community because of its propensity, in susceptible 
individuals, to cause coronary artery spasm leading to heart attacks 
and death.(9,75-81) Other significant side-effects are associated with 
the use of ephedra and ephedra-like substances: high blood pres-
sure, tachycardia, tremor, and restlessness are commonly associ-
ated with these products; left ventricular dysfunction has also been 
described following their use.(82) At one point ephedra accounted 
for 0.82% of all herbal product sales in the USA, but was impli-
cated in 64% of adverse reactions.(83) The use of products containing 
ephedra may be suspected in young, otherwise healthy individuals 
who present with angina, with evidence of coronary artery spasm 
or unexplained cerebrovascular symptoms.(84)
Athletes are frequent consumers of a variety of products, many of 
which may have the potential to produce cardiovascular side-
effects. In recent years, following the regulation of the use of 
ephedrine, other “ephedra-like” agents are now found in supple-
ment products the most common of which is bitter orange or citrus 
aurantium. This compound contains synephrine, a sympathomi-
metic agent with a structural similarity to ephedra alkaloids; it will 
inhibit the cytochrome P-450 system. Its safety profile is therefore 
open to question.(3,81) 
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It is impossible to comment on the safety or suitability of the wide 
variety of products offered to athletes as supplements and available 
over the internet.(85) To many athletes and their advisors, nutrition 
is virtually a religion not a scientific discipline, and supplements have 
particular appeal.
 
BLOOD DOPING AND ERYTHROPOIETIN
It has been known for years that accentuation of the red cell 
mass would enhance performance; infusion of blood was noted 
to increase running time to exhaustion by 23%!(86,87) At the 1984 
Los Angeles Olympic Games, US cyclists won gold medals after 
autologous and heterologous transfusions – controversy erupted in 
the aftermath. Blood doping was now a concern in sport; but the 
picture was to grow more complicated.
Erythropoietin, the natural stimulus for the production of red 
blood cells, is normally produced in the kidneys and exerts its 
influence on the bone marrow. The development of a synthetic 
product, rHuEPO, is a boon for patients with significant haema-
tological, renal, or oncologic disorders. Sadly, its ability to increase 
the production of red blood cells, with a resulting increase in 
aerobic capacity, has spawned widespread use of this product, and 
its successors, in a variety of sport cultures.(88)  Disastrous results for 
the health of athletes and the integrity of sport have followed.(89-91)
An increase in the red blood cell count invariably leads to an 
increase in blood viscosity and therefore may predispose to 
augmented clotting, which in turn may lead to the development of 
a variety of thrombotic complications including stroke, myocardial 
infarction and venous thromboembolism.(92) The abuse of rHuEPO 
products in sport settings, where dehydration is commonplace, may 
potentiate the likelihood of such untoward events.(93) A significant 
number of deaths were reported in cycling following the commer-
cial availability of rHuEPO in the late 1980s. The deaths have been 
imputed to the use of this hormonal product and its thrombo-
genic potential.(89) More insidious is the development of “red cell 
aplasia”; a life-threatening complication associated with the use of 
rHuEPO, and the result of the development of antibodies to 
erythropoietin with a resulting arrest of red cell production.(94) 
Concerns are now emerging regarding the relationship between 
the use of rHuEPO and the development of malignant tumours 
which themselves may be dependent upon the availability of blood 
supply.(95)
The use of rHuEPO was preceded, as noted, by “blood doping”, a 
process in which the blood of an athlete (an autologous transfu-
sion), or of others (a homologous transfusion), was infused so as 
to increase the red cell mass. Not surprisingly such administration 
was fraught with problems, including transfusion reactions.(86,96) The 
practice of blood doping declined, it is assumed, with the availability 
of rHuEPO. Sadly, now that technologies are available which 
make possible the detection of rHuEPO – and longer-acting agents 
have become available, it is believed that the re-administration of 
previously withdrawn red blood cells is increasing. We may have 
come full circle. These practices have typically been more pro-
nounced in “aerobic” sport, where endurance activity predominates.
CONCLUSION
Experience in sport leads one, at times, to believe that athletes are 
capable of the unimaginable in their quest for optimal performance. 
Considerations of doping and the associated health consequences 
expose the less attractive dimensions of sporting activities that, 
seen in another light, reflect some of the most celebrated aspects 
of human character. Sport is enthralling and empowering because 
it illuminates the human capacity to strive and excel; sport can 
be depressing or disillusioning when other, less admirable human 
qualities are revealed. Attempts to enhance sport performance 
artificially, pharmacologically, ultimately erode the sport experience 
for all. Clinicians should be aware of the cardiac signs and symp-
toms that might alert us to the use of performance-enhancing 
drugs, while serving as community exponents of sport that is more 
human – the result of training and dedication – not the product of 
a steroid biochemist. 
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